KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) EBIT Margin (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed EBIT Margin for 13 consecutive years, with 12.74% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin rose 6847.0% year-over-year to 12.74%, compared with a TTM value of 12.8% through Dec 2025, up 12608.0%, and an annual FY2025 reading of 12.8%, up 12608.0% over the prior year.
  • EBIT Margin was 12.74% for Q4 2025 at Travere Therapeutics, down from 62.32% in the prior quarter.
  • Across five years, EBIT Margin topped out at 62.32% in Q3 2025 and bottomed at 409.35% in Q4 2022.
  • Average EBIT Margin over 5 years is 159.84%, with a median of 112.7% recorded in 2024.
  • The sharpest move saw EBIT Margin soared 28615bps in 2021, then tumbled -46297bps in 2022.
  • Year by year, EBIT Margin stood at 53.62% in 2021, then crashed by -863bps to 409.35% in 2022, then surged by 49bps to 209.13% in 2023, then soared by 61bps to 81.21% in 2024, then surged by 84bps to 12.74% in 2025.
  • Business Quant data shows EBIT Margin for TVTX at 12.74% in Q4 2025, 62.32% in Q3 2025, and 11.05% in Q2 2025.